anti-ptk7/exatecan antibody-drug conjugate day301
anti-ptk7/exatecan antibody-drug conjugate day301: sourced relationships with 1 company · 1 clinical trial tracked.
anti-ptk7/exatecan antibody-drug conjugate day301 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could anti-ptk7/exatecan antibody-drug conjugate day301 → DAWN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) Advanced or Metastatic Solid Tumors | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients With Locally Advanced or Metastatic Solid Tumors
Primary endpoint: Phase 1a: Dose Escalation: Number of participants with reported Dose Limiting Toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with anti-ptk7/exatecan antibody-drug conjugate day301?
anti-ptk7/exatecan antibody-drug conjugate day301 has dated SEC/FDA relationship records for Day One Biopharmaceuticals, Inc..
How many clinical trials involve anti-ptk7/exatecan antibody-drug conjugate day301?
BioSniper tracks 1 clinical trial involving anti-ptk7/exatecan antibody-drug conjugate day301.